Metastatic Breast Cancer – Pipeline Review, H2 2016
- Pages: 1096
- Published: December 2016
- Report Code: GMDHC8794IDB
-
Global Markets Direct’s, ‘Metastatic Breast Cancer – Pipeline Review, H2 2016’, provides an overview of the Metastatic Breast Cancer pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Metastatic Breast Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Metastatic Breast Cancer and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
The report provides a snapshot of the global therapeutic landscape of Metastatic Breast Cancer
The report reviews pipeline therapeutics for Metastatic Breast Cancer by companies and universities/research institutes based on information derived from company and industry-specific sources
The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
The report reviews key players involved Metastatic Breast Cancer therapeutics and enlists all their major and minor projects
The report assesses Metastatic Breast Cancer therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
The report summarizes all the dormant and discontinued pipeline projects
The report reviews latest news related to pipeline therapeutics for Metastatic Breast Cancer
Reasons to buy
Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategiesIdentify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Identify and understand important and diverse types of therapeutics under development for Metastatic Breast Cancer
Identify potential new clients or partners in the target demographic
Develop strategic initiatives by understanding the focus areas of leading companies
Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
Devise corrective measures for pipeline projects by understanding Metastatic Breast Cancer pipeline depth and focus of Indication therapeutics
Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies mentioned
3SBio Inc
AB Science SA
AbbVie Inc
Acceleron Pharma Inc
Acetylon Pharmaceuticals Inc
Adgero Biopharmaceuticals Inc
Advaxis Inc
Advenchen Laboratories LLC
Alteogen Inc
Amarna Therapeutics BV
Ambrx Inc
Amgen Inc
Aphios Corp
Arvinas Inc
Aslan Pharmaceuticals Pte Ltd
Astellas Pharma Inc
Astex Pharmaceuticals Inc
AstraZeneca Plc
Bayer AG
Beta Pharma Inc
Biocon Ltd
Bionovis SA
Boehringer Ingelheim GmbH
Bristol-Myers Squibb Company
Cantex Pharmaceuticals Inc
Cascadian Therapeutics Inc
CASI Pharmaceuticals Inc
Celgene Corp
Celldex Therapeutics Inc
Cellectar Biosciences Inc
Celltrion Inc
Clovis Oncology Inc
Corcept Therapeutics Inc
CSPC Pharmaceutical Group Limited
Curadis GmbH
Curaxys SL
Daiichi Sankyo Company Ltd
Deciphera Pharmaceuticals LLC
DexTech Medical AB
Dompe Farmaceutici SpA
Dr. Reddy's Laboratories Ltd
EirGenix Inc
Eisai Co Ltd
Eli Lilly and Company
Ensol Biosciences Inc
EOS Biosciences Inc
Epigen Biosciences Inc
Etubics Corp
F. Hoffmann-La Roche Ltd
FibroGen Inc
Gene Techno Science Co Ltd
Genelux Corp
Genentech Inc
Genor BioPharma Co Ltd
Gilead Sciences Inc
Glycotope GmbH
GP Pharm SA
GTx Inc
Halozyme Therapeutics Inc
Hanmi Pharmaceuticals Co Ltd
Hetero Drugs Ltd
Humorigin Biotechnology Corp
Immune Design Corp
Immunomedics Inc
Immunophotonics Inc
Immupharma Plc
Incyte Corp
Intas Pharmaceuticals Ltd
Ionis Pharmaceuticals Inc
Jiangsu Hengrui Medicine Co Ltd
Johnson & Johnson
Kadmon Corp LLC
Kancera AB
Karyopharm Therapeutics Inc
Laboratoires Pierre Fabre SA
Mabion SA
MacroGenics Inc
MandalMed Inc
Meabco A/S
MedImmune LLC
Medivation Inc
Merck & Co Inc
Merck KGaA
Merrimack Pharmaceuticals Inc
Merus NV
MetaStat Inc
Millennium Pharmaceuticals Inc
Morphotek Inc
Mycenax Biotech Inc
NantKwest Inc
Natco Pharma Ltd
Nektar Therapeutics
Neonc Technologies Inc
NewLink Genetics Corp
Nippon Kayaku Co Ltd
Northwest Biotherapeutics Inc
Novartis AG
Oasmia Pharmaceutical AB
OBI Pharma Inc
Oncobiologics Inc
Oncolytics Biotech Inc
OncoMed Pharmaceuticals Inc
Ono Pharmaceutical Co Ltd
Panacea Pharmaceuticals Inc
Paras Biopharmaceuticals Finland Oy
Pfizer Inc
Pharma Mar SA
PIQUR Therapeutics AG
Plexxikon Inc
Polaris Pharmaceuticals Inc
Polyphor Ltd
Prescient Therapeutics Ltd
Prima BioMed Ltd
Puma Biotechnology Inc
Radius Health Inc
Richter Gedeon Nyrt
Samyang Holdings Corp
Sanofi
Seattle Genetics Inc
Shanghai Henlius Biotech Co Ltd
Sorrento Therapeutics Inc
Starpharma Holdings Ltd
Sun Pharma Advanced Research Company Ltd
SynCore Biotechnology Co Ltd
Syndax Pharmaceuticals Inc
Synthon Holdings BV
Taiho Pharmaceutical Co Ltd
Takeda Pharmaceutical Company Ltd
Tocagen Inc
Transgene Biotek Ltd
Tyme Technologies Inc
Vaxil Bio Therapeutics Ltd
Vertex Pharmaceuticals Inc
VioQuest Pharmaceuticals Inc
Vyriad Inc
Wilex AG
WntResearch AB
ZIOPHARM Oncology Inc
Zymeworks Inc
Table of Contents
List of Tables
List of Figures
Pricing
Discounts available for multiple report purchases.